Chromomycin A2 exhibits antileukemic effects by coordinated disruption of survival pathways (2025)
Source: Blood. Conference titles: ASH - Annual Meeting and Exposition. Unidades: ICB, FM
Subjects: FARMACOLOGIA, CÉLULAS SANGUÍNEAS, MEDULA ÓSSEA, SOBREVIVÊNCIA CELULAR, LEUCEMIA MIELOIDE AGUDA, ANTINEOPLÁSICOS, APOPTOSE, CITOMETRIA DE FLUXO, DANO AO DNA, WESTERN BLOTTING
ABNT
LIMA, Keli et al. Chromomycin A2 exhibits antileukemic effects by coordinated disruption of survival pathways. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2025-7848. Acesso em: 23 abr. 2026. , 2025APA
Lima, K., Vieira, E. O., Medeiros, R. de C. C., Nogueira, F. L., Costa-Lotufo, L. V., Machado Neto, J. A., & Rego, E. M. (2025). Chromomycin A2 exhibits antileukemic effects by coordinated disruption of survival pathways. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1182/blood-2025-7848NLM
Lima K, Vieira EO, Medeiros R de CC, Nogueira FL, Costa-Lotufo LV, Machado Neto JA, Rego EM. Chromomycin A2 exhibits antileukemic effects by coordinated disruption of survival pathways [Internet]. Blood. 2025 ; 146 7848-7849.[citado 2026 abr. 23 ] Available from: https://doi.org/10.1182/blood-2025-7848Vancouver
Lima K, Vieira EO, Medeiros R de CC, Nogueira FL, Costa-Lotufo LV, Machado Neto JA, Rego EM. Chromomycin A2 exhibits antileukemic effects by coordinated disruption of survival pathways [Internet]. Blood. 2025 ; 146 7848-7849.[citado 2026 abr. 23 ] Available from: https://doi.org/10.1182/blood-2025-7848
